Metformina Aurovitas

Metformin Hydrochloride, the active ingredient in Metformina Aurovitas, is a biguanide presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults.

GNH USA supplies Metformina Aurovitas as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina Aurovitas (metformin) is used to improve glycaemic control in disorders of glucose metabolism. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Prediabetes: helps delay progression to overt diabetes. - Polycystic ovary syndrome: improves insulin resistance and may restore ovulatory cycles.

Metformina Aurovitas may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, often transient. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycaemia: uncommon when used alone, more likely with other agents. - Vitamin B12 deficiency: may develop with long‑term therapy. - Pancreatitis: rare inflammation of the pancreas.

Before initiating Metformina Aurovitas, certain safety considerations are recommended. - Renal function assessment: avoid or adjust dose in patients with impaired kidney function. - Hepatic status review: monitor liver enzymes in those with liver disease. - Lactic acidosis risk: discontinue if signs of metabolic acidosis appear. - Concomitant medication review: evaluate for drugs that may increase metformin levels. - Elderly dosing: consider lower starting dose due to reduced renal reserve. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metformina Aurovitas can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast media: may precipitate renal impairment and lactic acidosis. - Cimetidine: can increase metformin plasma concentrations. - Certain antivirals (e.g., didanosine): elevate risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemic symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - NSAIDs: may reduce renal perfusion, increasing metformin exposure. - Warfarin: monitor INR as metformin may alter anticoagulant effect.